Norgine agrees distribution deal for Setofilm

Norgine has agreed an exclusive licensing agreement with APR and Labtec over the distribution rights to the ondansetron orally dispersible film strip product Setofilm.

The arrangement, which applies to Europe and selected nations in the Middle East, Africa and Australasia, will see Norgine take responsibility for commercialising the therapy option for chemotherapy and radiotherapy-induced nausea and vomiting.

Setofilm is currently registered in 16 European countries and is the first prescription product developed as an orodispersible film, making it ideal for patients such as children and the elderly, who might have difficulty with swallowing.

APR believes that the product will benefit from being aligned with a company of Norgine's recognised commercial and marketing capabilities in Europe.

Peter Stein, chief executive officer of Norgine, said: "We believe the product offers real benefits to patients and as such is an excellent addition to our existing products in supportive care."

Last month, Norgine announced the completion of enrolment for a clinical study of TZP-101, a treatment for bowel surgery patients it is developing alongside Tranzyme Pharma.